1. Profile Evidence, Fairness, and the Risks of Mistaken Convictions.Marcello Di Bello & Collin O’Neil - 2019 - Ethics 130 (2):147-178.
    Many oppose the use of profile evidence against defendants at trial, even when the statistical correlations are reliable and the jury is free from prejudice. The literature has struggled to justify this opposition. We argue that admitting profile evidence is objectionable because it violates what we call “equal protection”—that is, a right of innocent defendants not to be exposed to higher ex ante risks of mistaken conviction compared to other innocent defendants facing similar charges. We also show why admitting other (...)
    Direct download (4 more)  
    Export citation  
    Bookmark   3 citations  
  2.  7
    The Practice of Pharmaceutics and the Obligation to Expand Access to Investigational Drugs.Michael Buckley & Collin O’Neil - 2020 - Journal of Medicine and Philosophy 45 (2):193-211.
    Do pharmaceutical companies have a moral obligation to expand access to investigational drugs to patients outside the clinical trial? One reason for thinking they do not is that expanded access programs might negatively affect the clinical trial process. This potential impact creates dilemmas for practitioners who nevertheless acknowledge some moral reason for expanding access. Bioethicists have explained these reasons in terms of beneficence, compassion, or a principle of rescue, but their arguments have been limited to questions of moral permissibility, leaving (...)
    Direct download (4 more)  
    Export citation  
    Bookmark   2 citations  
  3.  35
    Methodological and Inducement Manipulation.Collin O’Neil - 2013 - American Journal of Bioethics 13 (11):55-57.